Overview

Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 OH deficiency.
Phase:
Phase 4
Details
Lead Sponsor:
Federico II University
Treatments:
Cortisol succinate
Cortisone
Cortisone acetate
Dexamethasone
Epinephrine
Epinephryl borate
Glucocorticoids
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Prednisolone
Prednisone
Racepinephrine